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Introduction
More than a decade ago, it became apparent that treat-
ment of HIV infection with only 1 antiretroviral agent was
associated with the rapid development of resistance.[1]
Clinical trials conducted at that time showed that combin-
ing 2 antiretroviral agents improved virologic and immu-
nologic responses, compared with use of a single agent.
Accordingly, 2-drug combination antiretroviral therapy
became the standard of care to maintain viral suppression
and minimize the emergence of resistant strains and,
thereby, reduce the risk of disease progression and death.
Subsequent experience and clinical trials showed that 3-
drug combinations were substantially more effective than
2-drug combinations. Recommended 3-drug regimens of
highly-active antiretroviral therapy (HAART) generally
include 2 nucleoside or nucleotide analog reverse tran-
scriptase inhibitors (NRTIs), plus 1 nonnucleoside analog
reverse transcriptase inhibitor (NNRTI) or 1 protease
inhibitor (PI).
There are 8 NRTIs, 9 PIs, 3 NNRTIs, and 1 fusion inhibitor,
as well as 4 coformulated NRTI combinations, currently
approved for use in the United States. The most recent US
Department of Health and Human Services (DHHS)
guidelines for initial therapy in HIV-infected adults and
adolescents include 91 potential HAART regimens: 70
combinations of 2 NRTIs plus a PI (of which 30 combina-
tions use a PI boosted with low-dose ritonavir), 20 com-
binations of 2 NRTIs plus an NNRTI, and 1 triple NRTI.[2]
Of the 90 potential combinations, 6 are designated "pre-
ferred" on the basis of trial results and expert opinion
(Table 1), and 84 are designated "alternative." One triple-
NRTI regimen is recommended only when an NNRTI- or
PI-based regimen cannot or should not be used as first-
line therapy.
This article will discuss some of these choices, focusing on
the role of NRTIs when constructing HIV regimens.
Historical Overview of Antiretroviral Therapy
The NRTIs were the first class of antiretroviral agents
found to be efficacious against HIV. As early as 1986,
treatment with the NRTI zidovudine was reported to
reduce the number of opportunistic infections, increase
the CD4+ cell count, and reduce mortality in patients with
AIDS.[3] Zidovudine was introduced in the United States
in 1987, followed by didanosine in 1991. Initial reports
indicated that monotherapy with these NRTIs was effec-
tive in patients with HIV infection.[3-7] It was observed as
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Table 1: Current "Preferred" Regimens for Initial Treatment of 
HIV Infection in Adults and Adolescents
DHHS Recommended Regimens
NNRTI-based EFV* + (ZDV or TDF) + (3TC or FTC)
PI-based LPV/r + ZDV + (3TC or FTC)
*Efavirenz is not recommended for use in first trimester pregnancy or 
in women who want to conceive or are not adhering to an effective 
contraceptive regimen.
DHHS = US Department of Health and Human Services; PI = 
protease inhibitor; ZDV = zidovudine; 3TC = lamivudine; FTC = 
emtricitabine; TDF = tenofovir disoproxil fumarate; NNRTI = 
nonnucleoside reverse transcriptase inhibitor
Adapted from Guidelines for the Use of Antiretroviral Agents in HIV-
1-Infected Adults and Adolescents. US Department of Health and 
Human Services. October 6, 2005Journal of the International AIDS Society 2006, 8:16 http://www.jiasociety.org/content/8/1/16
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early as 1989,[8] and confirmed between 1992[9] and
1994,[1,10] that control of HIV replication was not main-
tained by single-drug therapy with zidovudine[11,12] or
didanosine,[13] even when these drugs were used sequen-
tially.
Treatment regimens combining 2 NRTIs to reduce the
viral burden and delay the onset of drug resistance were
the subject of discussion by 1992,[14,15] when a third
NRTI, zalcitabine, was introduced for use only in combi-
nation with zidovudine. Subsequently, 2 large trials,
Delta[16] and the AIDS Clinical Trials Group (ACTG)
study 175,[17] showed that combination therapy with
zidovudine plus didanosine or zalcitabine substantially
reduced the risk of clinical progression or death, com-
pared with zidovudine alone. The majority of patients in
these studies had been treated with zidovudine prior to
enrollment. Another trial showed that the combination of
zidovudine plus didanosine or zalcitabine may be more
effective than zidovudine alone in patients with little or
no previous zidovudine therapy.[18] Three controlled tri-
als demonstrated that the combination of zidovudine and
lamivudine (3TC)  an NRTI introduced in 1995 for use in
combination with zidovudine  provided greater and more
sustained increases in CD4+ cell counts and decreases in
viral load than did continued zidovudine monotherapy,
when the combination was used in antiretroviral-naive
patients[19] or patients previously treated with zidovu-
dine.[20,21] A fourth NRTI, stavudine, was introduced in
1994 for use in patients who no longer responded to, or
who could not tolerate zidovudine, didanosine, or zalcit-
abine.
Following the introduction of the first PIs saquinavir and
indinavir in mid-1990s, it became apparent that 3-drug
combinations further improved the long-term immuno-
logic and virologic effects of therapy.[22-24] This led to
the construction of regimens with 3 or more antiretroviral
drugs to increase and prolong HIV suppression. Founded
on a large number of studies, the standard of care is now
a combination of 3 drugs, typically 2 NRTIs plus either a
PI or an NNRTI. One such study showed that the addition
of RTV to 2 NRTIs lowered the risk of AIDS-related com-
plications and prolonged survival.[23] Another study
showed that the addition of the NNRTI nevirapine to a
regimen of 2 NRTIs significantly increased the CD4+ cell
count and lowered the mean titer of infectious HIV-1 in
peripheral blood mononuclear cells.[22]
A sixth NRTI, abacavir, was approved in 1999, in combi-
nation with other antiretroviral agents, for the treatment
of HIV infection. This approval was based primarily on
the results of 2 studies, which demonstrated that abacavir/
zidovudine/lamivudine reduced viral loads more effec-
tively than zidovudine/lamivudine.[25] A seventh NRTI,
tenofovir disoproxil fumarate, was introduced in 2001
and was the first nucleotide agent approved for treatment
of HIV infection. Nucleoside analogs must be converted
to their triphosphate form in the cell by the enzymatic
addition of 3 phosphates, whereas tenofovir contains its
first phosphate, and requires 2 phosphorylation steps to
become active. A 3-year efficacy and safety study showed
that levels of viral suppression with tenofovir were com-
parable to those achieved with stavudine, when both
agents were given in combination with lamivudine/efa-
virenz.[26] Another NRTI, emtricitabine, was approved in
2003 for the treatment of HIV infection in adults in com-
bination with other antiretroviral agents. The chemical
structure of emtricitabine is nearly identical to that of lam-
ivudine, although emtricitabine has a somewhat longer
intracellular half-life than lamivudine.[27] Due to the
similarities of these NRTIs, much of the long safety and
efficacy experience with lamivudine has been extrapolated
to emtricitabine. A recent equivalence study showed that,
in patients adequately suppressed with lamivudine plus
either stavudine or zidovudine, those who switched from
lamivudine to emtricitabine had comparable 48-week
viral suppression compared with those who remained on
lamivudine.[28]
A marked decline in the progression of HIV infection to
AIDS and AIDS-related death began in 1996 following the
increasingly widespread use of potent 3-drug antiretrovi-
ral combinations as components of HAART.[29-33]
Despite this achievement, the large number of tablets and
capsules and complicated dosing schedules necessary for
early, triple-drug regimens led to problems with adher-
ence. The introduction of zidovudine/lamivudine as a
combined single tablet (Combivir, GlaxoSmithKline) in
1997 offered a simplified regimen and the possibility of
improved drug adherence. The introduction of this cofor-
mulation set the stage for the dual-NRTI coformulations
of tenofovir/emtricitabine (Truvada, Gilead Sciences) and
abacavir/lamivudine (Epzicom, GlaxoSmithKline), both
approved on August 2, 2004. Additionally, a triple combi-
nation of abacavir/zidovudine/lamivudine in a single tab-
let (Trizivir, GlaxoSmithKline) was approved in 2000.
Present Role of NRTIs in Combination Therapy
A major goal of HAART is to suppress plasma HIV RNA
below detectable levels by combining 3 or more antiretro-
viral agents from 1 or more classes. The use of agents from
different classes lessens the development of resist-
ance.[34] However, antiretroviral regimens containing
drugs from more than 2 classes are not routinely recom-
mended for patients who are treatment naive, because
those in whom a 3-class regimen fails may become resist-
ant to drugs in all 3 classes, leaving them with fewer
options for subsequent therapy. A HAART regimen should
have acceptable short- and long-term toxicity and must fitJournal of the International AIDS Society 2006, 8:16 http://www.jiasociety.org/content/8/1/16
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the patient's comorbidity profile and lifestyle.[35] Cur-
rently recommended initial HAART regimens specify the
use of 2 NRTIs and either an NNRTI or a PI.[2]
The rational selection of triple-drug regimens is based pri-
marily on the results of clinical trials, but also on the
potency and durability of response, drug toxicity, drug-
drug interactions, potential for resistant mutation selec-
tion, impact on future treatment, and dosing convenience
of the individual agents.[2] Although indirect compari-
sons of controlled trials of PI- vs NNRTI-based HAART
had been made,[36] until the final results of ACTG study
384 were published in December 2003, the clinical effec-
tiveness of PI- and NNRTI-based 3-drug combinations
had not been compared directly in randomized controlled
studies. Because zidovudine/lamivudine and stavudine/
didanosine had been compared previously in clinical tri-
als of 2-drug regimens and because of the favorable results
observed in these trials,[37,38] these NRTI combinations
have been frequently used in 3-drug regimens. NRTIs such
as zidovudine, which was introduced almost 2 decades
ago, continue to remain reliably effective when used in
current combination regimens when patients are adher-
ent.
The following provides an update on key studies of NRTIs
in combination therapy.
Zidovudine/lamivudine vs Stavudine/didanosinee
ACTG 384 was a large study designed to compare different
combination regimens in previously untreated
patients.[39,40] The NRTI backbones were zidovudine/
lamivudine or stavudine/didanosine. The first part of this
study examined treatment with one of four 3-drug regi-
mens until virologic failure, at which point patients were
switched to another 3-drug regimen that included none of
the first 3 drugs.[39] The second part of this study com-
pared these four 3-drug regimens with two 4-drug regi-
mens.[40] Patients treated with a 3-drug combination
received zidovudine/lamivudine or stavudine/didanosine
plus the PI nelfinavir or the NNRTI efavirenz, whereas
those treated with a 4-drug combination received one of
these NRTI combinations plus nelfinavir/efavirenz. The
results confirmed that the efficacy of antiretroviral drugs
depends on how they are combined. The combination of
stavudine/didanosine was inferior to that of zidovudine/
lamivudine[41] and was more toxic.[39] Compared with
the other 3-drug regimens, the regimen containing efa-
virenz/zidovudine/lamivudine as the first regimen
delayed failure of the first regimen, and using this combi-
nation as the first or second regimen delayed failure of the
second regimen.[39] In addition, there was no significant
difference in time to failure between a single 4-drug regi-
men and 2 consecutive 3-drug regimens.[40] While the 4-
drug regimens were effective, the simpler 3-drug regimen
of efavirenz/zidovudine/lamivudine emerged as the opti-
mal choice for the initiation of therapy.
Zidovudine/lamivudine/lopinavir/ritonavir
Although there are currently no published studies evaluat-
ing the efficacy of the 3-drug combination of zidovudine/
lamivudine and coformulated ritonavir-boosted lopinavir
for initial HAART, the tolerability of this combination was
assessed in the setting of postexposure prophylaxis and
then retrospectively compared with the tolerability of
zidovudine/lamivudine/nelfinavir.[42] The tolerability of
zidovudine/lamivudine/lopinavir/ritonavir appeared sig-
nificantly better than that of zidovudine/lamivudine/
nelfinavir (side effects: 64% vs 85%, respectively; P
<.003). Currently, the DHHS guidelines designated efa-
virenz and lopinavir/ritonavir both combined with a dual
NRTI backbone as "preferred" regimens. A large trial com-
paring the efficacy of lopinavir/ritonavir with that of efa-
virenz after initial treatment with coformulated
zidovudine/lamivudine in treatment-naive patients has
completed enrollment.[43] Until results are available
from this randomized trial, data remain limited. An open-
label study compared outcomes in 97 patients who
started therapy with efavirenz and lopinavir/ritonavir,
and found similar clinical outcomes between these 2 reg-
imens at 17 months.[44]
Zidovudine/lamivudine Plus Efavirenz or Indinavir
Several studies have evaluated the NRTI backbone of zido-
vudine/lamivudine combined with an NNRTI or an
unboosted PI. The open-label DuPont 006 study assessed
the NRTI backbone of zidovudine/lamivudine plus either
efavirenz or indinavir, with a third arm of efavirenz/indi-
navir.[45] Efficacy was similar with the NNRTI-based reg-
imen and the PI-based regimen, although the zidovudine/
lamivudine/efavirenz arm performed significantly better
than the PI-containing arms with respect to the primary
outcome measure of percentage of patients with suppres-
sion of plasma HIV RNA to undetectable levels.
The Merck 035 study assessed the durability of zidovu-
dine/lamivudine/indinavir.[46] Twenty of the 30 patients
receiving this combination still had a viral load < 50 cop-
ies/mL after 3 years.
Triple-NRTI Therapy
A number of studies have demonstrated that the combina-
tion of lamivudine/abacavir plus zidovudine or stavudine
provides a highly effective NRTI-backbone. CNA 3014
compared coformulated zidovudine/lamivudine plus a
third NRTI, abacavir with zidovudine/lamivudine plus a
PI, indinavir, in an open-label study.[47] At 48 weeks, the
proportion of patients with HIV RNA < 400 copies/mL
and < 50 copies/mL was 64% and 59%, respectively, in
the abacavir group and 50% and 48%, respectively, in theJournal of the International AIDS Society 2006, 8:16 http://www.jiasociety.org/content/8/1/16
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indinavir group. The higher level of adherence among
patients in the abacavir group may explain the higher
degree of virologic control among patients on this regi-
men.
ACTG 5095 compared coformulated zidovudine/lamivu-
dine/abacavir with 2 different NNRTI-based regimens:
zidovudine/lamivudine/efavirenz and coformulated
zidovudine/lamivudine/abacavir plus efavirenz.[48]
Coformulated zidovudine/lamivudine/abacavir alone
was less effective than the efavirenz-based regimens with
respect to change in viral load. The proportion of patients
with HIV RNA < 200 copies/mL at 48 weeks was 74% in
the zidovudine/lamivudine/abacavir arm, compared with
89% in the pooled efavirenz arms. Entry into the triple-
NRTI arm was discontinued prematurely.
In the Clinically Significant Long-term Antiretroviral
Sequential Sequencing (CLASS) Study, lamivudine/
abacavir were used in combination with a third NRTI, sta-
vudine: an NNRTI, efavirenz; or a ritonavir-boosted PI,
amprenavir.[49] Each regimen had similar activity based
on the proportion of subjects with plasma HIV-1 RNA lev-
els < 400 copies/mL at week 48 (80% vs 83% vs 75%,
respectively). However, lamivudine/abacavir/efavirenz
was more efficacious than the other combinations in a
secondary analysis using a cut-off of < 50 copies/mL (62%
vs 76% vs 59%, respectively for the third NNRTI, the
NNRTI, and the boosted PI regimens, respectively), and it
was also superior at achieving levels of < 400 copies/mL
among the subgroup of participants with a baseline viral
load > 100,000 copies/mL (55% vs 77% vs 53%, respec-
tively).
Other triple-NRTI combinations are less efficacious than
lamivudine/abacavir/zidovudine or lamivudine/abacavir/
stavudine. High rates of early virologic failure have
recently been reported among previously untreated HIV-
infected patients who received lamivudine/abacavir/teno-
fovir as initial therapy.[50] At week 8, 11 patients (58%)
failed to experience at least a 2-log10 decline from baseline
or had a viral rebound after initial viral suppression. In
another study, 20 of 21 patients treated with the combina-
tion of lamivudine/didanosine/tenofovir experienced
virologic failure (< 2 log10 reduction in plasma HIV RNA
level) at 12 weeks.[51] In both studies, treatment was
associated with the selection of the M184V/I mutation
with or without the K65R mutation (see below).
Quadruple Regimens
When given as initial HAART, 4-drug regimens have
shown promising preliminary results in recently com-
pleted studies as well as ongoing, comparative tri-
als.[40,52]
Results of the studies summarized here indicate that regi-
mens based on a dual-NRTI backbone plus an NNRTI or a
PI can be used as initial therapy for HIV infection. A triple-
NRTI regimen of abacavir/zidovudine/lamivudine can be
considered as an alternative under certain circumstances
disfavoring the use of the "one-plus-two" regimens based
on a PI or NNRTI with 2 NRTIs.
NRTI Resistance
Viral mutations decrease the susceptibility of HIV to
antiretroviral agents by the selection of resistant strains.
Combination therapy can block this selection process
because multiple drugs suppress viral replication more
effectively than single agents.[34] Although now consid-
ered suboptimal, dual-NRTI regimens do provide a higher
barrier to resistance than does single-NRTI therapy,[53]
and studies of 2-drug combinations permit the assess-
ment of viral mutations without the potentially con-
founding effect of a third or fourth agent.
NRTIs arrest the synthesis of viral DNA by reverse tran-
scriptase.[34] Resistance is conferred by several mecha-
nisms, including the loss of affinity of the NRTI for the
HIV reverse transcriptase. For example, the M184V muta-
tion involves the substitution of methionine with valine
at position 184 of reverse transcriptase. While M184V is
the main mutation that confers resistance to lamivudine,
it also increases sensitivity to zidovudine by decreasing
the efficiency of excision of the incorporated drug.[54]
The K65R mutation, which involves the replacement of
lysine by arginine at position 65, and the L74V mutation
are particularly associated with abacavir- or tenofovir-con-
taining containing regimens and appears to confer resist-
ance to most NRTIs with the exception of zidovudine.[53]
The L74V mutation is also associated with abacavir resist-
ance, but does not generally confer broad cross-resistance
to other NRTIs. The Q151M complex of mutations, which
involves the replacement of glutamine by methionine at
position 151, is most often associated with the failure of
regimens containing stavudine and didanosine, but can
confer resistance to all NRTIs.[53]
Resistance to NRTIs is also conferred by removal of thymi-
dine analogs such as zidovudine and stavudine from the
prematurely terminated DNA chain[34]; accordingly
these are called thymidine analog mutations (TAMs),
although cross-resistance to other NRTIs can occur. Stud-
ies of dual-NRTI regimens, including zidovudine/lamivu-
dine and stavudine/lamivudine, have shown that
zidovudine and stavudine are similar in their tendency to
select for thymidine analog mutations.[55-60] Kuritzkes
and colleagues[57] observed that resistance to zidovudine
and stavudine emerged at comparable rates in patients
treated with either of these NRTIs, although the zidovu-
dine/lamivudine arm showed a greater tendency towardJournal of the International AIDS Society 2006, 8:16 http://www.jiasociety.org/content/8/1/16
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development of 2 or more thymidine analog mutations.
Sarmati and coworkers[58] found that zidovudine-like
resistance mutations in zidovudine-naive patients
appeared to correlate with virologic failure during long-
term stavudine therapy; among 10 patients failing treat-
ment with stavudine/lamivudine, 9 had zidovudine-like
resistance mutations. Other investigators, however, have
found a relatively low incidence of zidovudine-like resist-
ance mutations among patients treated with stavu-
dine.[59,60]
In the ACTG 384 study, subjects in 3-drug groups who
began therapy with lamivudine/zidovudine/efavirenz had
fewer treatment failures with resistance to NRTIs (7.7%)
than did those who began therapy with didanosine/stavu-
dine/efavirenz (16.1%, P = .02); in addition, each of the 3
groups that began therapy with didanosine/stavudine had
a higher incidence of serious toxic effects than the groups
that began therapy with lamivudine/zidovudine.[40] Fig-
ures 1, 2 and 3 show the proportion of patients who had
regimen failure with resistance to study drugs, by treat-
ment group.
The most frequent mutations conferring resistance to
NRTIs were detected at position 184 (80%), which is asso-
ciated with increased sensitivity to zidovudine; mutations
conferring resistance occurred with a frequency of only
3% at position 65. There were relatively few first regimen
failures during the study in the group that began therapy
with lamivudine/zidovudine/efavirenz.
In a dose-escalating, in vitro study of tenofovir-based 2-
drug combinations, tenofovir alone selected for K65R
only, while abacavir alone selected for M184V followed
by K65R and other mutations (Y115F, L74V).[61] The
combination of tenofovir/abacavir selected for K65R fol-
lowed by another mutation (Y115F), whereas the combi-
nation of tenofovir/lamivudine selected only for K65R.
These results suggest that K65R is the major mutation
selected by tenofovir alone or in combination with
abacavir or lamivudine.
The dual-NRTI combinations of abacavir/lamivudine,
abacavir/zidovudine, and lamivudine/zidovudine with or
without nelfinavir were compared in HIV-infected chil-
dren in the Pediatric European Network for Treatment of
AIDS 5 study.[62] Plasma HIV RNA decreased by 2.6 log10
copies/mL in the abacavir/lamivudine group, compared
with 1.7 and 2.2 log10 copies/mL in the lamivudine/zido-
vudine and abacavir/zidovudine groups, respectively.
M184V and thymidine analog mutations were prevalent
among children receiving lamivudine/zidovudine, while
abacavir/zidovudine selected for thymidine analog muta-
tions only, and abacavir/lamivudine selected for M184V,
K65R, and other mutations (Y115F, L74V).[63]
In summary, these results indicate that treatment with
zidovudine or stavudine plus lamivudine or emtricitabine
allows the preservation of future treatment options
because selection for M184V occurs first, is accompanied
by the slow accumulation of thymidine analog mutations
over a period of months after initial virologic failure, and
rarely selects for K65R. In fact, zidovudine may actually
prevent selection of K65R. In addition, the extensive
resistance data available for NRTIs generally (and for
older agents such as zidovudine, stavudine and lamivu-
dine particularly) allow clinicians to anticipate outcomes
and manage resistance more effectively.
Percentage of subjects who had regimen failure with resist- ance to NRTIs according to Treatment Group Figure 1
Percentage of subjects who had regimen failure with 
resistance to NRTIs according to Treatment Group. 
For subjects in groups 1 (initial therapy = didanosine/stavu-
dine/efavirenz), 2 (initial therapy = didanosine/stavudine/nelfi-
navir), 3 (lamivudine/zidovudine/efavirenz), and 4 
(lamivudine/zidovudine/nelfinavir), the bars show the cumula-
tive percentage of subjects with drug resistance at the time 
of the first or second regimen failure; for subjects in groups 5 
(initial therapy = didanosine/stavudine/efavirenz/nelfinavir 
ddI/d4T/EFV/NFV) and 6 lamivudine/zidovudine/efavirenz/
nelfinavir), the bars show the percentage of subjects with 
new drug-resistance mutations after the failure of their first 
regimen. Drug-resistance mutations were identified through 
the sequencing of the HIV-1 reverse transcriptase and pro-
tease of virus isolated from subjects with virologic failure or 
toxicity-related failure who had plasma HIV-1 RNA levels of 
at least 1000 copies/mL. From Shafer RW, Smeaton LM, Rob-
bins GK, et al. Comparison of 4-drug regimens and pairs of 
sequential 3-drug regimens as initial therapy for HIV-1 infec-
tion. N Engl J Med. 2003; 349: 23042315, with permission of 
the publisher, Massachusetts Medical Society.
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Metabolic Changes and Adverse Effects 
Associated With NRTI-Based Regimens
Most pharmacokinetic interactions between antiretrovi-
rals are related to the hepatic cytochrome P450 (CYP450)
enzyme system, which all NNRTIs and PIs can alter,
thereby affecting drug metabolism and plasma levels.[64]
NRTIs, unlike NNRTIs and PIs, are not metabolized by the
CYP450 system and, with the exception of zidovudine
and abacavir, undergo elimination through the renal,
rather than hepatic route. Accordingly, there is little
potential for interaction between NRTIs and either
NNRTIs or PIs that could adversely alter the plasma con-
centrations of these agents. However, activity of NRTIs is
dependent on the intracellular concentration of their
phosphorylated forms, and the effects of antiretrovirals or
other medications on membrane transporters may lead to
changes in intracellular levels.
Some adverse effects of HAART have been well described,
such as the increased risk for lipoatrophy associated with
thymidine analogs such as stavudine, and to a lesser
extent, zidovudine. In one study, the incidence of clinical
lipodystrophy (mainly lipoatrophy) was significantly
greater among HIV-infected patients receiving stavudine/
lamivudine/indinavir compared with those receiving
zidovudine/lamivudine/indinavir.[65] Replacing stavu-
dine with zidovudine or abacavir has been shown to
improve stavudine-induced lipoatrophy while maintain-
Percentage of subjects who had regimen failure with resist- ance to NRTIs according to Treatment Group Figure 3
Percentage of subjects who had regimen failure with 
resistance to NRTIs according to Treatment Group. 
Percentage of subjects who had regimen failure with resist-
ance to PIs according to Treatment Group. For subjects in 
groups 1 (initial therapy = didanosine/stavudine/efavirenz), 2 
(initial therapy = didanosine/stavudine/nelfinavir), 3 (lamivu-
dine/zidovudine/efavirenz), and 4 (lamivudine/zidovudine/
nelfinavir), the bars show the cumulative percentage of sub-
jects with drug resistance at the time of the first or second 
regimen failure; for subjects in groups 5 (initial therapy = 
didanosine/stavudine/efavirenz/nelfinavir ddI/d4T/EFV/NFV) 
and 6 lamivudine/zidovudine/efavirenz/nelfinavir), the bars 
show the percentage of subjects with new drug-resistance 
mutations after the failure of their first regimen. Drug-resist-
ance mutations were identified through the sequencing of the 
HIV-1 reverse transcriptase and protease of virus isolated 
from subjects with virologic failure or toxicity-related failure 
who had plasma HIV-1 RNA levels of at least 1000 copies/
mL. From Shafer RW, Smeaton LM, Robbins GK, et al. Com-
parison of 4-drug regimens and pairs of sequential 3-drug 
regimens as initial therapy for HIV-1 infection. N Engl J Med. 
2003; 349: 23042315, with permission of the publisher, Mas-
sachusetts Medical Society.
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Percentage of subjects who had regimen failure with resist- ance to NRTIs according to Treatment Group Figure 2
Percentage of subjects who had regimen failure with 
resistance to NRTIs according to Treatment Group. 
Percentage of subjects who had regimen failure with resist-
ance to NNRTIs according to Treatment Group. For sub-
jects in groups 1 (initial therapy = didanosine/stavudine/
efavirenz), 2 (initial therapy = didanosine/stavudine/nelfina-
vir), 3 (lamivudine/zidovudine/efavirenz), and 4 (lamivudine/
zidovudine/nelfinavir), the bars show the cumulative percent-
age of subjects with drug resistance at the time of the first or 
second regimen failure; for subjects in groups 5 (initial ther-
apy = didanosine/stavudine/efavirenz/nelfinavir ddI/d4T/EFV/
NFV) and 6 lamivudine/zidovudine/efavirenz/nelfinavir), the 
bars show the percentage of subjects with new drug-resist-
ance mutations after the failure of their first regimen. Drug-
resistance mutations were identified through the sequencing 
of the HIV-1 reverse transcriptase and protease of virus iso-
lated from subjects with virologic failure or toxicity-related 
failure who had plasma HIV-1 RNA levels of at least 1000 
copies/mL. From Shafer RW, Smeaton LM, Robbins GK, et al. 
Comparison of 4-drug regimens and pairs of sequential 3-
drug regimens as initial therapy for HIV-1 infection. N Engl J 
Med. 2003; 349: 23042315, with permission of the publisher, 
Massachusetts Medical Society.
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Table 2: Selected Investigational Antiretroviral Drugs in Phase 23 Studies
Class Agent Manufacturer
NRTI Alovudine (MIV-310) Medivir
Amdoxovir (DAPD) RFS Pharmaceuticals
AVX754 Avexa
Elvucitabine (ACH-126) Achillion
Racivir (PSI 5004) Pharmasset
Reverset (D-D4FC) Pharmasset
NNRTI 695634 GlaxoSmithKline
Calanolide A Sarawak MediChem
DPC 083 Bristol-Myers Squibb
Etravirine (TMC 125) Tibotec
MIV-150 Medivir
TMC-278 Tibotec
PI DPC-681 Bristol-Myers Squibb
GW640385 GlaxoSmithKline
L-756423 Merck
RO0334649 Roche
TMC-114 Tibotec
Fusion/Entry Inhibitor AMD070 Anormed
Aplaviroc* GlaxoSmithKline
BMS-488043 Bristol-Myers Squibb
FP-21399 EMD Lexigen
Maraviroc (UK 427) Pfizer
PRO 140 Progenics
PRO 542 Progenics
TNX-355 Tanox
Vicriviroc (SCH 417) Schering
NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = nonnucleoside reverse transcriptase inhibitor; PI = protease inhibitor. Adapted from 
"2005 Antiretrovirals Pipeline," available at: http://www.aidsinfonyc.org (accessed December 8, 2005) and from the University of California at San 
Francisco Center for HIV Information, "FDA-Approved and Investigational Antiretrovirals," available at: http://hivinsite.ucsf.edu/ (accessed 
December 6, 2005).
* Development halted October 2005.Journal of the International AIDS Society 2006, 8:16 http://www.jiasociety.org/content/8/1/16
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ing HIV suppression.[66] In addition, switching HIV-
infected patients from stavudine and/or PI-containing
regimens to coformulated zidovudine/lamivudine plus
abacavir was associated with objective evidence of limb
fat sparing and fat restoration, while maintaining HIV
suppression.[67] A combination of stavudine/lamivu-
dine/efavirenz compared with tenofovir/lamivudine/efa-
virenz TDF found a higher rate of lipodystrophy in the
stavudine/lamivudine/efavirenz (12% vs 1%).[68] Other
potential adverse effects of antiretroviral drugs used in ini-
tial HAART regimens may necessitate careful patient mon-
itoring. For example, a number of reports have linked
renal tubular dysfunction and acute renal failure with ten-
ofovir.[69-73]
Future Directions
Optimization of current regimens and the development of
new antiretroviral agents should increase the benefits of
HAART over time.
Adherence remains crucial to the long-term success of
HAART. Regimens with once- or twice-daily dosing and
regimens with fewer pills per day may improve adher-
ence[74] and possibly long-term viral suppression.[75-
77] The availability of simpler dosing regimens, aided by
the combination of 2 or 3 antiretrovirals in a single pill,
has improved adherence. With respect to combination
therapy, the adherence benefit of newer, once-daily dos-
age formulations may be limited by the fact that other
drugs in the HAART regimen still require more frequent
dosing, or dosing at the same frequency but at different
times secondary to food requirements or potential inter-
actions. Furthermore, missing a once-daily dose may have
a greater potential to result in suboptimal drug levels,
compared with missing a single dose of more frequently
administered formulations.[52]
New agents from existing antiretroviral classes, novel for-
mulations of existing drugs, and antiretrovirals from new
classes are becoming available. Many of these new
options offer advantages in terms of convenience, and
some retain antiviral activity against HIV strains that are
resistant to other drugs.[34] Examples of such new ther-
apy options are the PIs atazanavir (taken once daily) and
fosamprenavir (taken once daily with ritonavir or twice
daily with or without ritonavir), which were approved in
2003. The PI tipranavir (approved June 22, 2005), when
administered with ritonavir, is active against HIV in some
patients whose previous PI-based therapy has failed. Enfu-
virtide, a fusion inhibitor, is an example of a new drug
class offering activity against HIV resistant to other antiret-
roviral classes.[78,79] In addition, many promising new
agents are on the horizon. Table 2 summarizes key inves-
tigational agents from existing antiretroviral classes, as
well as those from potentially novel drug classes, which
are being actively investigated phase 2 or 3 studies.
Discussion
Initial antiretroviral therapy should consist of 3 agents,
including 2 NRTIs/NtRTIs and a PI or an NNRTI. Use of
such regimens is based on established durability, potency
and efficacy, and well-characterized safety and resistance
profiles. For some patients, the "preferred" regimens may
not appropriate, and alternatives, such as boosted and
unboosted PI-based regimens, or triple-NRTI regimens
that contain a thymidine analog (abacavir/lamivudine/
zidovudine), can be considered. Although several novel
regimen configurations, such as quadruple NRTIs, dual
PIs, and NRTI-sparing regimens have been examined,
none of these approaches has showed great promise.
Certain antiretroviral combinations should be avoided
because of toxicity risks. These combinations include
didanosine/stavudine and tenofovir/didanosine. In addi-
tion, efavirenz should not be used in pregnant women,
women planning pregnancy, or sexually active women
who are not adhering to a proven contraceptive. Triple-
NRTI regimens that do not include zidovudine or stavu-
dine should also be avoided, due to a high rate of early
virologic failure and selection of resistance.
In addition to safety and efficacy concerns, different dual-
NRTI backbones have unique resistance profiles that
should be considered when making treatment decisions.
Specifically, zidovudine plus either lamivudine or emtric-
itabine selects for M184V initially, and can subsequently
select for thymidine analog mutations; tenofovir plus
either lamivudine or emtricitabine frequently selects for
M184V, and sometimes selects for M184V and K65R;
abacavir plus either lamivudine or emtricitabine fre-
quently selects for M184V and infrequently selects for
M184V and L74V. These mutational patterns should
inform the selection of initial and subsequent therapies.
In addition to these considerations, the tactical sequenc-
ing of certain combinations may avoid class resistance
and preserve future treatment options.
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